We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.05 | 1.52% | 3.35 | 3.30 | 3.40 | 3.35 | 3.30 | 3.30 | 164,059 | 15:18:31 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 0 | -2.37M | -0.0262 | -1.28 | 3.02M |
From Apr 2019 to Apr 2024
TIDMVAL
RNS Number : 4699E
ValiRx PLC
09 February 2018
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Issue of options and directors dealings
London, UK., 9 February 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces it has awarded options to directors and key management. The options may be exercised at a price of 4 pence per share at any time up until 7 February 2028.
Hot Features
Premium
Name of Director Number of Option Total number % of existing
Existing Award of Options share
Options* capital
------------------ ---------- ----------- ------------- --------------
Oliver de
Giorgio-Miller 555,000 2,750,000 3,305,000 0.8%
------------------ ---------- ----------- ------------- --------------
Dr Satu Vainikka 694,000 3,625,000 4,319,000 1.1%
------------------ ---------- ----------- ------------- --------------
Dr George
Morris 597,000 3,125,000 3,722,000 0.9%
------------------ ---------- ----------- ------------- --------------
Gerry Desler 592,960 3,000,000 3,592,960 0.9%
------------------ ---------- ----------- ------------- --------------
Kevin Alexander 545,000 2,500,000 3,045,000 0.7%
------------------ ---------- ----------- ------------- --------------
Others 429,000 2,300,000 2,279,000 0.6%
------------------ ---------- ----------- ------------- --------------
Total 3,412,960 17,300,000 20,712,960 5.0%
------------------ ---------- ----------- ------------- --------------
*existing options are exercisable at a price between 43.125p - 125p
The issued share capital of the Company comprises 407,462,717 ordinary shares of 0.1 pence per shares. The table below illustrates the existing equity holdings of the directors:
Name of Director Total number % of existing
of shares share
capital
------------------ ------------- --------------
Oliver de
Giorgio-Miller 59,555 0.015%
------------------ ------------- --------------
Dr Satu Vainikka 624,909 0.15%
------------------ ------------- --------------
Dr George
Morris 588,287 0.14%
------------------ ------------- --------------
Gerry Desler 541,875 0.13%
------------------ ------------- --------------
Kevin Alexander 104,278 0.026%
------------------ ------------- --------------
Total 1,918,904 0.46%
------------------ ------------- --------------
***S ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20
3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20
3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879
458 364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP Tel: +44 (0) 20
(Nominated Adviser) 7213 0880
Liam Murray/Jo Turner/Richard
Nash
Beaufort Securities Limited Tel: +44 (0) 207
(Broker) 382 8300
Jon Belliss
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
------------------------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
----- -----------------------------------------------------------------
a. Name Oliver de Giorgio-Miller
----- ---------------------------- -----------------------------------
2 Reason for
notification
----- ---------------------------- -----------------------------------
a. Position/Status Director
----- ---------------------------- -----------------------------------
b. Initial notification/ Initial notification
Amendment
----- ---------------------------- -----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
----- -----------------------------------------------------------------
a. Name ValiRx Plc
----- ---------------------------- -----------------------------------
b. LEI 213800VQKB9SJCQDET40
----- ---------------------------- -----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
----- -----------------------------------------------------------------
a. Description
of the financial Options over ordinary shares
instrument,
type of instrument
Identification ISIN: GB00BWWYSP41
Code
----- ---------------------------- -----------------------------------
b. Nature of the Grant of options
transaction
----- ---------------------------- -----------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s) per share
----- ---------------------------- ----------------- -------------
4p 2,750,000
----------------- -------------
Aggregated
information
- Aggregated
Volume 2,750,000
d. - Price 4p
----- ---------------------------- -----------------------------------
e. Date of the 9 February 2018
transaction
----- ---------------------------- -----------------------------------
f. Place of the AIM
transaction
----- ---------------------------- -----------------------------------
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
------------------------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
----- -----------------------------------------------------------------
a. Name Dr Satu Vainikka
----- ---------------------------- -----------------------------------
2 Reason for
notification
----- ---------------------------- -----------------------------------
a. Position/Status Director
----- ---------------------------- -----------------------------------
b. Initial notification/ Initial notification
Amendment
----- ---------------------------- -----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
----- -----------------------------------------------------------------
a. Name ValiRx Plc
----- ---------------------------- -----------------------------------
b. LEI 213800VQKB9SJCQDET40
----- ---------------------------- -----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
----- -----------------------------------------------------------------
a. Description
of the financial Options over ordinary shares
instrument,
type of instrument
Identification ISIN: GB00BWWYSP41
Code
----- ---------------------------- -----------------------------------
b. Nature of the Grant of options
transaction
----- ---------------------------- -----------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s) per share
----- ---------------------------- ----------------- -------------
4p 3,625,000
----------------- -------------
Aggregated
information
- Aggregated
Volume 3,625,000
d. - Price 4p
----- ---------------------------- -----------------------------------
e. Date of the 9 February 2018
transaction
----- ---------------------------- -----------------------------------
f. Place of the AIM
transaction
----- ---------------------------- -----------------------------------
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
------------------------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
----- -----------------------------------------------------------------
a. Name Dr George Morris
----- ---------------------------- -----------------------------------
2 Reason for
notification
----- ---------------------------- -----------------------------------
a. Position/Status Director
----- ---------------------------- -----------------------------------
b. Initial notification/ Initial notification
Amendment
----- ---------------------------- -----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
----- -----------------------------------------------------------------
a. Name ValiRx Plc
----- ---------------------------- -----------------------------------
b. LEI 213800VQKB9SJCQDET40
----- ---------------------------- -----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
----- -----------------------------------------------------------------
a. Description
of the financial Options over ordinary shares
instrument,
type of instrument
Identification ISIN: GB00BWWYSP41
Code
----- ---------------------------- -----------------------------------
b. Nature of the Grant of options
transaction
----- ---------------------------- -----------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s) per share
----- ---------------------------- ----------------- -------------
4p 3,125,000
----------------- -------------
Aggregated
information
- Aggregated
Volume 3,125,000
d. - Price 4p
----- ---------------------------- -----------------------------------
e. Date of the 9 February 2018
transaction
----- ---------------------------- -----------------------------------
f. Place of the AIM
transaction
----- ---------------------------- -----------------------------------
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
------------------------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
----- -----------------------------------------------------------------
a. Name Gerry Desler
----- ---------------------------- -----------------------------------
2 Reason for
notification
----- ---------------------------- -----------------------------------
a. Position/Status Director
----- ---------------------------- -----------------------------------
b. Initial notification/ Initial notification
Amendment
----- ---------------------------- -----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
----- -----------------------------------------------------------------
a. Name ValiRx Plc
----- ---------------------------- -----------------------------------
b. LEI 213800VQKB9SJCQDET40
----- ---------------------------- -----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
----- -----------------------------------------------------------------
a. Description
of the financial Options over ordinary shares
instrument,
type of instrument
Identification ISIN: GB00BWWYSP41
Code
----- ---------------------------- -----------------------------------
b. Nature of the Grant of options
transaction
----- ---------------------------- -----------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s) per share
----- ---------------------------- ----------------- -------------
4p 3,000,000
----------------- -------------
Aggregated
information
- Aggregated
Volume 3,000,000
d. - Price 4p
----- ---------------------------- -----------------------------------
e. Date of the 9 February 2018
transaction
----- ---------------------------- -----------------------------------
f. Place of the AIM
transaction
----- ---------------------------- -----------------------------------
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
------------------------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
----- -----------------------------------------------------------------
a. Name Kevin Alexander
----- ---------------------------- -----------------------------------
2 Reason for
notification
----- ---------------------------- -----------------------------------
a. Position/Status Director
----- ---------------------------- -----------------------------------
b. Initial notification/ Initial notification
Amendment
----- ---------------------------- -----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
----- -----------------------------------------------------------------
a. Name ValiRx Plc
----- ---------------------------- -----------------------------------
b. LEI 213800VQKB9SJCQDET40
----- ---------------------------- -----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
----- -----------------------------------------------------------------
a. Description
of the financial Options over ordinary shares
instrument,
type of instrument
Identification ISIN: GB00BWWYSP41
Code
----- ---------------------------- -----------------------------------
b. Nature of the Grant of options
transaction
----- ---------------------------- -----------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s) per share
----- ---------------------------- ----------------- -------------
4p 2,500,000
----------------- -------------
Aggregated
information
- Aggregated
Volume 2,500,000
d. - Price 4p
----- ---------------------------- -----------------------------------
e. Date of the 9 February 2018
transaction
----- ---------------------------- -----------------------------------
f. Place of the AIM
transaction
----- ---------------------------- -----------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAFANESSPEFF
(END) Dow Jones Newswires
February 09, 2018 06:57 ET (11:57 GMT)
1 Year Valirx Chart |
1 Month Valirx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
